Information Provided By:
Fly News Breaks for March 29, 2017
VRTX
Mar 29, 2017 | 05:49 EDT
Citi analyst Robyn Karnauskas raised her price target for Vertex Pharmaceuticals to $124 saying the successful VX-661 data remove a "key overhang from future development plans." The triple combo success more likely as VX-661is the key component in the triple combo, Karnauskas tells investors in a research note. Efficacy appeared slightly better relative to Orkambi while the safety profile looks significantly better for VX-661/Kalydeco combo in homozygous cystic fibrosis patients, the analyst contends. She keeps a Buy rating on Vertex.